Clostridium novyi Type B alpha toxin (TcnA)

Clostridium novyi Type B alpha toxin (TcnA) is a potent exotoxin and the primary virulence factor produced by the anaerobic bacterium Clostridium novyi Type B [1, 6]. It belongs to the family of large clostridial glucosylating toxins (LCGTs), which also includes toxins from Clostridioides difficile [8]. The toxin functions as a glucosyltransferase that inactivates host Rho family GTPases, such as Rho, Rac, and Cdc42, by attaching an N-acetylglucosamine moiety to a conserved threonine residue [8, 12]. This modification disrupts the actin cytoskeleton, leading to cell rounding, loss of barrier function, and eventually cell death [8, 14]. In livestock, particularly sheep and cattle, the toxin is responsible for infectious necrotic hepatitis, also known as Black Disease, characterized by severe liver necrosis and sudden death [5, 6]. Therapeutic intervention primarily involves the use of the Clostridium novyi Type B toxoid, an inactivated form of the toxin, which serves as a vaccine antigen to stimulate the production of protective neutralizing antibodies [9, 11]. Monitoring of vaccine efficacy is typically performed by measuring serum antitoxin titers using neutralization assays or ELISA [9, 14].

Other names

Alpha toxinTcnAClostridium novyi alpha-toxinLethal toxin of Clostridium novyiClostridium novyi Type B toxoid

The toxoid acts as an immunogenic antigen to stimulate the production of neutralizing antibodies (antitoxins) that bind to the native Alpha toxin, preventing its entry into host cells and neutralizing its enzymatic activity against Rho GTPases.